Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

This study has been completed.
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000358
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
  Purpose

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.


Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
Drug: Lofexidine
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   21 Years to 59 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000358

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Charles O'Brien, M.D., Ph.D. PDVAMC Treatment Research Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000358     History of Changes
Other Study ID Numbers: NIDA-3-0012-7, Y01-3-0012-7
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance Withdrawal Syndrome
Substance-Related Disorders
Mental Disorders
Lofexidine
Analgesics, Opioid
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on April 17, 2014